DE69433723D1 - Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen - Google Patents

Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen

Info

Publication number
DE69433723D1
DE69433723D1 DE69433723T DE69433723T DE69433723D1 DE 69433723 D1 DE69433723 D1 DE 69433723D1 DE 69433723 T DE69433723 T DE 69433723T DE 69433723 T DE69433723 T DE 69433723T DE 69433723 D1 DE69433723 D1 DE 69433723D1
Authority
DE
Germany
Prior art keywords
compositions used
used therefor
vivo administration
biological substances
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433723T
Other languages
English (en)
Other versions
DE69433723T3 (de
DE69433723T2 (de
Inventor
Mark W Grinstaff
Patrick Soon-Shiong
Michael Wong
Paul A Sandford
Kenneth S Suslick
Neil P Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
American Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69433723(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/023,698 external-priority patent/US5439686A/en
Priority claimed from US08/035,150 external-priority patent/US5362478A/en
Application filed by American Bioscience Inc filed Critical American Bioscience Inc
Application granted granted Critical
Publication of DE69433723D1 publication Critical patent/DE69433723D1/de
Publication of DE69433723T2 publication Critical patent/DE69433723T2/de
Publication of DE69433723T3 publication Critical patent/DE69433723T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE69433723T 1993-02-22 1994-02-22 Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen Expired - Lifetime DE69433723T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/023,698 US5439686A (en) 1993-02-22 1993-02-22 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US23698 1993-02-22
US35150 1993-03-26
US08/035,150 US5362478A (en) 1993-03-26 1993-03-26 Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
PCT/US1994/001985 WO1994018954A1 (en) 1993-02-22 1994-02-22 Methods for in vivo delivery of biologics and compositions useful therefor

Publications (3)

Publication Number Publication Date
DE69433723D1 true DE69433723D1 (de) 2004-05-27
DE69433723T2 DE69433723T2 (de) 2005-02-24
DE69433723T3 DE69433723T3 (de) 2008-10-30

Family

ID=26697503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433723T Expired - Lifetime DE69433723T3 (de) 1993-02-22 1994-02-22 Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen

Country Status (16)

Country Link
US (4) US5498421A (de)
EP (1) EP0693924B2 (de)
JP (1) JP3746293B2 (de)
CN (1) CN1245156C (de)
AT (1) ATE264671T1 (de)
AU (1) AU673057B2 (de)
BR (1) BR9405798A (de)
CA (1) CA2155947C (de)
DE (1) DE69433723T3 (de)
DK (1) DK0693924T4 (de)
ES (1) ES2219646T5 (de)
HK (1) HK1097449A1 (de)
NO (1) NO314017B1 (de)
NZ (1) NZ262679A (de)
PT (1) PT693924E (de)
WO (1) WO1994018954A1 (de)

Families Citing this family (389)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US20030073642A1 (en) * 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5997904A (en) * 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DE69433723T3 (de) * 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5855865A (en) * 1993-07-02 1999-01-05 Molecular Biosystems, Inc. Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
EP0804249A2 (de) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US5965109A (en) * 1994-08-02 1999-10-12 Molecular Biosystems, Inc. Process for making insoluble gas-filled microspheres containing a liquid hydrophobic barrier
AUPM922594A0 (en) * 1994-11-04 1994-11-24 Commonwealth Scientific And Industrial Research Organisation Reduction of methane production in animals
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
GB9502065D0 (en) * 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US6540981B2 (en) 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
CA2214088A1 (en) * 1995-03-03 1996-09-12 Metabolex Inc. Novel encapsulation process by a gelling polymer
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
GB9506844D0 (en) * 1995-04-03 1995-05-24 Armitage Ian M Pharmaceutical microencapsulation
AU693354B2 (en) * 1995-04-10 1998-06-25 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
EP0831935A4 (de) * 1995-06-07 2001-08-29 Mallinckrodt Medical Inc Gasförmige ultraschallkontrastmittel und dazugehörige verfahren
WO2004073750A1 (en) * 1995-06-07 2004-09-02 Harald Dugstad Improvements in or relating to contrast agents
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US20020119102A1 (en) * 1996-06-05 2002-08-29 Alexey Kabalnov Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients
FR2736930B1 (fr) * 1995-07-17 1997-09-19 Biocem Procede de production, par des cellules vegetales, de proteines heminiques, proteines ainsi obtenues et produits contenant ces proteines
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
JP2000500744A (ja) † 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
US6270795B1 (en) * 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5767297A (en) * 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
US5753477A (en) * 1996-03-19 1998-05-19 University Technology Corporation Magneto-biolistic methods
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US5773461A (en) * 1996-06-06 1998-06-30 Bristol-Myers Squibb Company 7-deoxy-6-substituted paclitaxels
JP2001508762A (ja) * 1996-06-27 2001-07-03 ジー．ディー．サール アンド カンパニー 架橋した外殻領域および内部芯領域を有する両親媒性コポリマーからなり、医薬およびその他の用途に有用な粒子
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US6017310A (en) * 1996-09-07 2000-01-25 Andaris Limited Use of hollow microcapsules
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
CA2263568C (en) 1996-09-11 2008-12-02 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a contrast agent and a renal vasodilator
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6083484A (en) 1996-10-17 2000-07-04 Molecular Biosystems, Inc. Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents
CA2270120A1 (en) * 1996-10-28 1998-05-07 Pal Rongved Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6413763B1 (en) 1996-11-12 2002-07-02 The University Of Akron Method of removing gas from a site using gas vesicles of cells
US9107949B2 (en) 1996-11-12 2015-08-18 The University Of Akron Method for using naturally occurring gas vesicles as ultrasound contrast agent
US5804551A (en) * 1996-11-12 1998-09-08 Baxter International Inc. Pretraumatic use of hemoglobin
US6036940A (en) * 1996-11-12 2000-03-14 The University Of Akron Compositions and methods relating to the production, isolation, and modification of gas vesicles
WO1998023298A1 (en) * 1996-11-25 1998-06-04 Imarx Pharmaceutical Corp. Perfluorinated-ether compositions as diagnostic contrast agents
US6068600A (en) * 1996-12-06 2000-05-30 Quadrant Healthcare (Uk) Limited Use of hollow microcapsules
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
ES2388248T3 (es) * 1997-03-31 2012-10-11 Boston Scientific Scimed Limited Forma de dosificación que comprende taxol en forma cristalina
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
DE19720083A1 (de) * 1997-05-14 1998-11-19 Silvia Zender Arzneimittel
US6245318B1 (en) * 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
CA2206739C (en) * 1997-06-03 2006-10-10 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
SG165156A1 (en) * 1997-06-27 2010-10-28 Abraxis Bioscience Llc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
KR100789008B1 (ko) * 1997-06-27 2007-12-26 아브락시스 바이오사이언스 인크. 신규 약물 제제
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6045777A (en) * 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP1007673B1 (de) 1997-07-30 2008-12-17 Emory University Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
JP2001517686A (ja) * 1997-09-26 2001-10-09 ユーエイビー リサーチ ファンデーション 抗原性を減弱させた血球および、その利用法
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6726934B1 (en) * 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
WO1999022769A1 (en) 1997-10-31 1999-05-14 Monsanto Company Gellan gum tablet coating
WO1999024016A1 (en) * 1997-11-10 1999-05-20 Sonus Pharmaceuticals, Inc. Emulsions for aerosolization and drug delivery
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US5851544A (en) * 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
AU3895499A (en) * 1998-05-11 1999-11-29 Purdue Research Foundation Methods and compositions for nucleic acid delivery
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
AU3969099A (en) * 1998-05-13 1999-11-29 Light Sciences Limited Partnership Controlled activation of targeted radionuclides
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US7427602B1 (en) * 1998-05-13 2008-09-23 The Regents Of The University Of Michigan Sustained DNA delivery from structural matrices
EP1002810A4 (de) * 1998-06-04 2002-07-17 Kao Corp Polymeremulsion und verfahren zu deren herstellung
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US20020022588A1 (en) * 1998-06-23 2002-02-21 James Wilkie Methods and compositions for sealing tissue leaks
ATE252889T1 (de) * 1998-08-19 2003-11-15 Skyepharma Canada Inc Injizierbare wässerige propofoldispersionen
US6485747B1 (en) 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE19852928C1 (de) 1998-11-17 2000-08-03 Steffen Panzner Strukturen in Form von Hohlkugeln
US6864301B2 (en) * 1998-11-30 2005-03-08 The Regents Of The University Of Colorado Preparation and use of photopolymerized microparticles
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
MXPA01007777A (es) 1999-02-01 2003-10-06 Eidgenoess Tech Hochschule Bio-materiales formadas por reaccion de adicion nucleofila a grupos insaturados conjugados.
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6444192B1 (en) * 1999-02-05 2002-09-03 The Regents Of The University Of California Diagnostic imaging of lymph structures
WO2000050050A1 (en) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Multiparticulate formulation
US6767928B1 (en) * 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
DK1163018T3 (da) * 1999-03-19 2003-09-29 Univ Michigan Technology Man W Mineralisering og cellulær mønstring på biomaterialeoverflader
US6398772B1 (en) * 1999-03-26 2002-06-04 Coraje, Inc. Method and apparatus for emergency treatment of patients experiencing a thrombotic vascular occlusion
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US6426145B1 (en) 1999-05-20 2002-07-30 Scimed Life Systems, Inc. Radiopaque compositions for visualization of medical devices
EP1102784A4 (de) * 1999-06-07 2009-12-30 Mirus Bio Corp Eine verbindung mit einer labilen disulfid-bindung
CN1211153C (zh) * 1999-09-10 2005-07-20 辛根塔有限公司 变释微胶囊
AU7743200A (en) * 1999-10-06 2001-05-10 Imarx Therapeutics, Inc. Improved methods for delivering bioactive agents
WO2001026617A1 (de) * 1999-10-08 2001-04-19 Coty B.V. Kosmetische wirkstoffzubereitung mit synergistisch erhöhtem radikalschutzfaktor
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US7129329B1 (en) * 1999-12-06 2006-10-31 University Of Hawaii Heme proteins hemAT-Hs and hemAT-Bs and their use in medicine and microsensors
JP2003522806A (ja) * 2000-02-15 2003-07-29 ジェンザイム、コーポレーション 改良された薬物送達のための生体高分子の修飾
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
WO2001064164A2 (en) 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method
DE10010264A1 (de) 2000-03-02 2001-09-13 Novosom Gmbh Stabilisierte Liposomen und Hüllstrukturen
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1292285A4 (de) * 2000-06-02 2009-07-22 Eisai Corp North America Darreichungssystem für bioaktive stoffe
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US20020076443A1 (en) * 2000-06-19 2002-06-20 Stanley Stein Multiple phase cross-linked compositions and uses thereof
EP1355965B1 (de) * 2000-10-19 2012-09-19 Ecole Polytechnique Fédérale de Lausanne (EPFL) Verfahren zur herstellung von blockcopolymeren für multifunktionelle selbstorganisierende systeme
US20060280724A1 (en) * 2000-11-04 2006-12-14 Ferguson Ian A Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers
DE10108799A1 (de) * 2001-02-19 2002-09-05 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur Ultraschallimpfung von biologischem Zellmaterial
US20030044468A1 (en) * 2001-03-20 2003-03-06 Francesco Cellesi Two-phase processing of thermosensitive polymers for use as biomaterials
JP5175020B2 (ja) * 2001-04-30 2013-04-03 サイティミューン サイエンシーズ， インコーポレイテッド コロイド状金属組成物および方法
DE60229848D1 (de) * 2001-06-21 2008-12-24 Beth Israel Hospital - und organtransplantationen und unterdrückt apoptose
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US6797257B2 (en) * 2001-06-26 2004-09-28 The Board Of Trustees Of The University Of Illinois Paramagnetic polymerized protein microspheres and methods of preparation thereof
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
JP4426288B2 (ja) * 2001-07-10 2010-03-03 ソノジーン，リミテッド ライアビリティー カンパニー 肝臓へのｄｎａのトランスフェクションの増強
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20060051424A1 (en) * 2001-10-03 2006-03-09 Johns Hopkins University Compositions of oral gene therapy and methods of using same
NZ531944A (en) * 2001-10-19 2006-03-31 Isotechnika Inc Synthesis of cyclosporin analogs
WO2003049701A2 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
EP1319423A3 (de) 2001-12-11 2003-10-08 Dornier Medtech System GmbH Gerät und Verfahren zur Auslösung chemischer Reaktionen und zur gezielten Verabreichung von Medikamenten oder anderen Substanzen
JP3816809B2 (ja) * 2002-01-30 2006-08-30 株式会社日立製作所 薬剤、薬剤キャリア、薬剤の製造方法及び腫瘍の治療方法
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
IL148299A (en) * 2002-02-21 2014-04-30 Technion Res & Dev Foundation Ultrasonic to the heart
DE10211886B4 (de) * 2002-03-18 2004-07-15 Dornier Medtech Gmbh Verfahren und Einrichtung zum Erzeugen bipolarer akustischer Impulse
US20030179692A1 (en) * 2002-03-19 2003-09-25 Yoshitaka Ohotomo Storage medium
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
CA2481786A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
EP1499333B1 (de) * 2002-04-15 2015-06-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Kohlenmonoxid zur verwendung in einem verfahren zur behandlung von ileus
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
WO2003098232A2 (en) * 2002-05-17 2003-11-27 Case Western Reserve University Chemical shift markers for improved wireless fiducial marker tracking
MXPA04011426A (es) 2002-05-17 2005-10-19 Univ Yale Metodo para tratar la hepatitis.
DE10223196B4 (de) * 2002-05-24 2004-05-13 Dornier Medtech Systems Gmbh Verfahren und Einrichtung zum Transferieren von Molekülen in Zellen
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
US20040131703A1 (en) * 2002-06-21 2004-07-08 Bach Fritz H. Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
ES2321083T3 (es) * 2002-07-15 2009-06-02 Alcon, Inc. Pelicula bioerosionable para la administracion oftalmica de farmacos.
WO2004009134A1 (en) * 2002-07-22 2004-01-29 Bracco Imaging S.P.A. Procedures of cellular labelling with paramagnetic complexes for mri applications
EP2277551B1 (de) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
KR100514092B1 (ko) * 2002-11-23 2005-09-13 한국생명공학연구원 양이온성 고분자 물질과 음이온성 고분자 물질을 이용한 새로운 다중 유전자 전달 복합체
IL153124A (en) * 2002-11-27 2010-06-30 Herbal Synthesis Corp Solid composition that can be glued to the lining
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US7311926B2 (en) * 2002-12-20 2007-12-25 Battelle Memorial Institute Biocomposite materials and methods for making the same
FR2848854B1 (fr) 2002-12-24 2005-03-18 Coletica Particules comprenant un biopolymere degradable sous l'effet d'une onde electromagnetique telle qu'emise par un rayonnement solaire
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US7623908B2 (en) 2003-01-24 2009-11-24 The Board Of Trustees Of The University Of Illinois Nonlinear interferometric vibrational imaging
JP2004290745A (ja) * 2003-03-25 2004-10-21 Ajinomoto Co Inc マイクロカプセルの製造法
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7217410B2 (en) * 2003-06-17 2007-05-15 The Board Of Trustees Of The Universtiy Of Illinois Surface modified protein microparticles
US7198777B2 (en) * 2003-06-17 2007-04-03 The Board Of Trustees Of The University Of Illinois Optical contrast agents for optically modifying incident radiation
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US7217270B2 (en) * 2003-09-08 2007-05-15 Mectra Labs, Inc. Method and material for coating electro-cautery probes and lubricating surgical instruments
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
EP1694301A4 (de) * 2003-12-02 2009-11-18 Cytimmune Sciences Inc Verfahren und zusammensetzungen zur herstellung von monoklonalen antikörpern
US7610074B2 (en) * 2004-01-08 2009-10-27 The Board Of Trustees Of The University Of Illinois Multi-functional plasmon-resonant contrast agents for optical coherence tomography
AU2005209169B2 (en) 2004-01-16 2010-12-16 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20050175584A1 (en) * 2004-01-28 2005-08-11 Paciotti Giulio F. Functionalized colloidal metal compositions and methods
WO2005097208A2 (en) * 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Tissue oxygenation measurements
WO2005103080A2 (en) * 2004-04-21 2005-11-03 Albert Einstein College Of Medicine Of Yeshiva University Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1773303A2 (de) * 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
KR101313027B1 (ko) * 2004-06-23 2013-10-02 신타 파마슈티칼스 코프. 암 치료용 비스(티오-히드라지드 아미드) 염
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
US7289840B2 (en) 2004-09-22 2007-10-30 Receptomon, Llc Method for monitoring early treatment response
WO2006045050A1 (en) * 2004-10-19 2006-04-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Methods and compositions for protecting cells from ultrasound-mediated cytolysis
DE602005019367D1 (de) * 2004-12-15 2010-04-01 Dornier Medtech Systems Gmbh Verbesserte Zelltherapie und Gewebsregeneration mittels Stosswellen bei Patienten mit kardiovaskulären and neurologischen Krankheiten
MX2007009354A (es) * 2005-02-03 2008-01-14 Epix Pharm Inc Metodos de perfusion en estado estable.
US7622102B2 (en) * 2005-02-08 2009-11-24 Receptomon, Llc Method for monitoring early treatment response
MX339142B (es) * 2005-02-18 2016-05-13 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US7586618B2 (en) * 2005-02-28 2009-09-08 The Board Of Trustees Of The University Of Illinois Distinguishing non-resonant four-wave-mixing noise in coherent stokes and anti-stokes Raman scattering
EP1865840A4 (de) * 2005-04-05 2009-10-21 Receptomon Llc Verfahren zur überwachung früher reaktionen auf behandlungen
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
US7725169B2 (en) * 2005-04-15 2010-05-25 The Board Of Trustees Of The University Of Illinois Contrast enhanced spectroscopic optical coherence tomography
NZ562572A (en) * 2005-04-15 2011-01-28 Synta Pharmaceuticals Corp Combination cancer therapy with BIS (thiohydrazide) amide compounds
EP1891141B1 (de) * 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
DE112006000047T5 (de) * 2005-06-30 2007-10-11 Amtec Co., Ltd. Eine Indikatorzusammensetzung zum Bewerten der Reinigung eines medizinischen Instrumentes
KR101457834B1 (ko) * 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
TWI429452B (zh) 2005-08-31 2014-03-11 Abraxis Bioscience Llc 包含弱水溶性藥劑及抗微生物劑之組合物
WO2007067417A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US7787129B2 (en) 2006-01-31 2010-08-31 The Board Of Trustees Of The University Of Illinois Method and apparatus for measurement of optical properties in tissue
DE602007005366D1 (de) * 2006-04-07 2010-04-29 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
US7744928B2 (en) * 2006-04-14 2010-06-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treatment of lesioned sites of body vessels
WO2007120911A2 (en) 2006-04-14 2007-10-25 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
CA2660524A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceutical Corp. Compounds for treating proliferative disorders
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
EP3470071A1 (de) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Brustkrebstherapie auf basis des hormonrezeptorstatus mit nanopartikel mit taxan
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
KR20150002886A (ko) * 2007-03-07 2015-01-07 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
WO2008124165A2 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
JP2010526159A (ja) * 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
EP2826462A1 (de) * 2007-04-10 2015-01-21 Saint Simeon Lda. Neuartige Zusammensetzungen mit Lysozym und C-1/C-4-Polysacchariden und Verwendung davon in der Mundpflege, Kosmetologie und Dermatologie, Kontrazeption, Urologie und Gynäkologie
ES2381639T3 (es) 2007-04-13 2012-05-30 Kuros Biosurgery Ag Sellante polimérico para tejidos
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
PT2155255E (pt) 2007-05-09 2013-10-15 Nitto Denko Corp Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
DK2155254T3 (da) * 2007-05-09 2013-03-04 Nitto Denko Corp Med platinlægemidler konjugerede polymere
PL2155188T3 (pl) 2007-06-01 2014-03-31 Abraxis Bioscience Llc Sposoby i kompozycje do leczenia nawrotowego raka
AU2008275578B2 (en) 2007-07-10 2014-04-10 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
AU2008302035A1 (en) * 2007-09-21 2009-03-26 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
SI2644594T1 (sl) 2007-09-28 2017-10-30 Pfizer Inc. Ciljanje rakavih celic z uporabo nanodelcev
WO2009062151A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8618056B2 (en) 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8115934B2 (en) 2008-01-18 2012-02-14 The Board Of Trustees Of The University Of Illinois Device and method for imaging the ear using optical coherence tomography
US7751057B2 (en) 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
US8983580B2 (en) 2008-01-18 2015-03-17 The Board Of Trustees Of The University Of Illinois Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
KR20100122510A (ko) * 2008-03-06 2010-11-22 닛토덴코 가부시키가이샤 중합체 파클리탁셀 접합체 및 암 치료 방법
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
JP2011517683A (ja) * 2008-04-10 2011-06-16 アブラクシス バイオサイエンス， エルエルシー 疎水性タキサン誘導体の組成物およびその使用
TWI573806B (zh) 2008-04-17 2017-03-11 巴克斯歐塔公司 生物活性胜肽
DE102008045152A1 (de) * 2008-07-09 2010-01-14 Universität Duisburg-Essen Künstliche Sauerstoffträger und ihre Verwendung
CN101642570B (zh) * 2008-08-07 2012-09-05 江苏大学附属医院 一氧化碳释放分子和肝素在制备治疗脓毒症药物中的应用
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (de) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
US8870848B2 (en) 2008-10-31 2014-10-28 Medtronic, Inc. System and method for delivery of biologic agents
US20100114057A1 (en) * 2008-10-31 2010-05-06 Medtronic, Inc. System and method for delivery of biologic agents
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
ES2773766T3 (es) * 2008-12-19 2020-07-14 Baxalta GmbH Inhibidores de TFPI y métodos de uso
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
US11235062B2 (en) * 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
MY175260A (en) 2009-04-15 2020-06-17 Abraxis Bioscience Llc Prion free nanoparticle compositions and methods of making thereof
EP3064230B1 (de) 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Verwendung von nanokristallen für einen wirkstofffreisetzungsballon
WO2011014704A2 (en) 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US11285494B2 (en) 2009-08-25 2022-03-29 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
US10751464B2 (en) 2009-08-25 2020-08-25 Nanoshell Company, Llc Therapeutic retrieval of targets in biological fluids
US10099227B2 (en) 2009-08-25 2018-10-16 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
WO2011025756A1 (en) 2009-08-25 2011-03-03 Agnes Ostafin Method and apparatus for continuous removal of submicron sized particles in a closed loop liquid flow system
PT2501234T (pt) * 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2011069082A2 (en) * 2009-12-04 2011-06-09 The Regents Of The University Of Michigan Red blood cell-mimetic particles and methods for making and use thereof
US9333189B2 (en) * 2010-02-03 2016-05-10 Oncbiomune, Inc. Taxane- and taxoid-protein compositions
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
MX359413B (es) 2010-03-26 2018-09-27 Abraxis Bioscience Llc Metodos de tratamiento de carcinoma hepatocelular.
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
NZ703047A (en) 2010-03-29 2016-11-25 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
US10806383B2 (en) * 2010-05-04 2020-10-20 Massachusetts Institute Of Technology Implantable dissolved oxygen sensor and methods of use
NZ604031A (en) 2010-06-04 2015-05-29 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ES2386177B1 (es) * 2010-09-21 2013-09-23 Lipotec, S.A. Nanocapsulas conteniendo microemulsiones
US9482861B2 (en) 2010-10-22 2016-11-01 The Regents Of The University Of Michigan Optical devices with switchable particles
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
CN109288789A (zh) 2011-04-28 2019-02-01 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
LT2717898T (lt) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc. Pro-koagulianto junginiai ir jų gavimo būdai
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
WO2013036973A2 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
WO2013084207A1 (pt) 2011-12-07 2013-06-13 Universidade Do Minho Formulações micelares proteicas e respectivo método de produção
WO2013090634A1 (en) 2011-12-14 2013-06-20 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
GB201221305D0 (en) * 2012-11-27 2013-01-09 Greater Glasgow Health Board Improved methods of assessing metabolic function
DK2827883T3 (da) 2012-03-21 2019-07-29 Baxalta GmbH Tfpi-inhibitorer og fremgangsmåder til anvendelse
WO2013151682A1 (en) 2012-04-06 2013-10-10 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
WO2013158895A1 (en) * 2012-04-18 2013-10-24 University Of Utah Research Foundation Novel echogenic contrast agents
US9335910B2 (en) 2012-04-23 2016-05-10 Tandem Diabetes Care, Inc. System and method for reduction of inadvertent activation of medical device during manipulation
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9715327B2 (en) 2012-06-07 2017-07-25 Tandem Diabetes Care, Inc. Preventing inadvertent changes in ambulatory medical devices
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
DK2921166T3 (en) * 2012-11-15 2017-10-02 Utah-Inha Dds & Advanced Therapeutics Res Center Biodegradable microbeads with improved adsorption capacity for anticancer drugs, containing albumin and dextran sulfate, as well as manufacturing process thereof
WO2014085633A1 (en) 2012-11-30 2014-06-05 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
MX370662B (es) 2013-03-12 2019-12-19 Abraxis Bioscience Llc Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014143808A1 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Hollow particles encapsulating a biological gas and methods of use
WO2014144364A1 (en) 2013-03-15 2014-09-18 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
CN110152005B (zh) 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
US9421329B2 (en) 2013-03-15 2016-08-23 Tandem Diabetes Care, Inc. Infusion device occlusion detection system
JP6625966B2 (ja) 2013-03-15 2019-12-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 希ガスが豊富な液体ならびにその調製及び使用の方法
CA2916865A1 (en) 2013-06-24 2014-12-31 Anthrogenesis Corporation Methods of expanding t cells
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
US20150140537A1 (en) * 2013-11-19 2015-05-21 Spectra Group Limited, Inc. Blood simulant for simulatoin-based medical trauma training
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
CN107072963B (zh) 2014-09-03 2020-07-07 吉倪塞思公司 治疗性纳米粒子和相关的组合物、方法和系统
AU2015317336B2 (en) 2014-09-18 2021-01-21 Tonix Pharma Holdings Limited Eutectic formulations of Cyclobenzaprine hydrochloride
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
PL3313401T3 (pl) 2015-06-29 2022-02-07 Abraxis Bioscience, Llc Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych
CN105901706B (zh) * 2016-04-21 2019-01-25 长江大学 一种鹅血抗氧化水解物及其微胶囊的制备方法
TR201606102A2 (tr) * 2016-05-10 2016-10-21 Tolgay Tuyan Ilhan Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz
WO2018160752A1 (en) 2017-02-28 2018-09-07 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
WO2019183146A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2020115283A1 (en) 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
WO2020114615A1 (en) 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
EP4037816A4 (de) * 2019-10-04 2023-10-18 The Regents Of The University Of Colorado, A Body Corporate Mikrometergrosse tröpfchen mit festem endoskelett oder exoskelett, das die thermische stabilität der flüssigkeitströpfchen verbessert
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN112891566A (zh) * 2019-12-04 2021-06-04 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种纳米材料及其制备方法和包含其的造影剂
US11366091B2 (en) * 2020-02-11 2022-06-21 Saudi Arabian Oil Company High temperature high pressure (HTHP) cell in sum frequency generation (SFG) spectroscopy for oil/brine interface analysis with reservoir conditions and dynamic compositions
CN112546406B (zh) * 2020-11-20 2022-04-22 广东药科大学 一种微型机器人给药装置及给药系统
WO2023164487A1 (en) * 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
WO2024046999A1 (de) 2022-08-31 2024-03-07 Johann Wolfgang Goethe-Universität Frankfurt am Main Lecithin-modifizierte nanoskalierte sauerstoffträger (lenox)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
JPS5933017B2 (ja) * 1980-03-14 1984-08-13 株式会社成和化成 マイクロカプセル用壁財
US4558032A (en) * 1981-12-31 1985-12-10 Neomed Inc. Synthetic whole blood substitute and a method of making the same
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
DE3376660D1 (en) * 1983-06-22 1988-06-23 Stolle Res & Dev Encapsulated cells, their method of preparation and use
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
EP0321481B1 (de) * 1986-08-28 1994-06-01 Enzacor Properties Limited Mikrogranuläre zubereitung zur verabreichung biologisch aktiver stoffe in den eingeweideregionen von tieren
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
SE8704158L (sv) * 1987-10-26 1989-04-27 Carbomatrix Ab C O Ulf Schroed Mikrosfaerer, foerfarande foer framstaellning daerav och anvaendning daerav
IE61591B1 (en) * 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
NO176278C (no) * 1988-08-24 1995-03-08 Allied Colloids Ltd Fremgangsmåte for fremstilling av en partikkelformig blanding av aktiv bestanddel i et polymert materiale
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
ATE99546T1 (de) * 1989-05-01 1994-01-15 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekuelen.
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5250283A (en) * 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
WO1991015947A1 (en) * 1990-04-17 1991-10-31 Isp Investments Inc. Preparation of discrete microdroplets of an oil in water stabilized by in situ polymerization of a water-soluble vinyl monomer
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
GB9106686D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
DE69433723T3 (de) * 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor

Also Published As

Publication number Publication date
US5498421A (en) 1996-03-12
DE69433723T3 (de) 2008-10-30
DK0693924T3 (da) 2004-08-09
CN1245156C (zh) 2006-03-15
EP0693924B2 (de) 2008-04-09
CA2155947A1 (en) 1994-09-01
DK0693924T4 (da) 2008-08-04
CA2155947C (en) 2007-08-21
CN1118136A (zh) 1996-03-06
US20090048331A1 (en) 2009-02-19
HK1097449A1 (en) 2007-06-29
ATE264671T1 (de) 2004-05-15
NO953278D0 (no) 1995-08-21
PT693924E (pt) 2004-09-30
ES2219646T5 (es) 2008-11-01
US5639473A (en) 1997-06-17
EP0693924A1 (de) 1996-01-31
US5635207A (en) 1997-06-03
DE69433723T2 (de) 2005-02-24
AU6249094A (en) 1994-09-14
WO1994018954A1 (en) 1994-09-01
JP3746293B2 (ja) 2006-02-15
EP0693924A4 (de) 1997-08-06
JPH08507075A (ja) 1996-07-30
AU673057B2 (en) 1996-10-24
NO314017B1 (no) 2003-01-20
ES2219646T3 (es) 2004-12-01
BR9405798A (pt) 1995-12-12
NZ262679A (en) 1997-08-22
NO953278L (no) 1995-10-13
EP0693924B1 (de) 2004-04-21

Similar Documents

Publication Publication Date Title
DE69433723D1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DE69428040D1 (de) Orale darreichungsform
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ES2186769T3 (es) Complejos estables que comprenden lipidos para la administracion de farmacos y procedimientos para su produccion.
DE794794T1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
DE69620877D1 (de) Arzneimittelformulierungen für il-12
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE140918T1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
DE69325393T2 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ATE198278T1 (de) Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
DE60032372D1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
DE60035504D1 (de) Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung
RU95101840A (ru) Сложные эфиры циклогексанола и содержащий их фармацевтический препарат
ATE106874T1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE357243T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: ABRAXIS BIOSCIENCE, INC., LOS ANGELES, CALIF., US

8327 Change in the person/name/address of the patent owner

Owner name: ABRAXIS BIOSCIENCE,LLC (N. D. GES. D.STAATES D, US